Kazazian Asset Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Kazazian Asset Management’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-18,281	Closed	-$836K	–	93
2017 Q4	$836K	Sell	18,281 -1,020	-5%	-$50.9K	0.85%	29
2017 Q3	$866K	Buy	19,301 +4,994	+35%	+$170K	1.06%	23
2017 Q2	$428K	Buy	+14,307	New	+$353K	0.65%	31
2015 Q4	–	Sell	-13,376	Closed	-$544K	–	94
2015 Q3	$544K	Buy	13,376 +526	+4%	+$23.1K	0.69%	31
2015 Q2	$685K	Buy	+12,850	New	+$682K	0.68%	26

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Kazazian Asset Management's JUNO Position: Q1 2018 in Review

Kazazian Asset Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 18,281 shares — an estimated $836K sold.

Kazazian Asset Management first reported a position in JUNO in Q2 2015 and held it in 5 quarters. The position peaked at $866K in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Kazazian Asset Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Kazazian Asset Management sold 18,281 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $836K.
Kazazian Asset Management first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 5 quarters.
Kazazian Asset Management's Juno Therapeutics, Inc. position peaked at $866K in Q3 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Kazazian Asset Management's 13F filing for Q1 2018, filed 15 May 2018.